Canada: Exporting Dietary Supplements From The U.S. To Canada: A Canadian Perspective

Manufacturers and distributors intending to market their U.S. dietary supplements in Canada will want to understand the key differences between the regulation of dietary supplements in the U.S. compared to their regulation in Canada.


Dietary supplements, which are classified as foods in the U.S., are typically classified as drugs in Canada, and are therefore subject to greater regulatory attention.

Under the Dietary Supplements Health and Education Act, dietary supplements are defined by reference to their ingredients: specifically, whether the product contains a "dietary ingredient" that is intended to supplement the diet, including vitamins, minerals, herbs or other botanicals, amino acids, enzymes, organ tissues and metabolites.1 Dietary supplements may be formulated as tablets, capsules or powders, but may also take more "food-like" forms such as drink and energy bars. Since these products are regulated as foods, manufacturers are not required to submit evidence of safety or efficacy to the FDA before products go to market.

Conversely, with the exception of a few specific products,2 most products classified as dietary supplements in the U.S. would be classified as natural health products (NHPs) in Canada.3 NHPs are regulated as drugs in Canada, although under a different regime than classic prescription drugs. The Natural Health Product Regulations apply to NHPs, whereas the Food and Drug Regulations apply to prescription drugs. NHPs are defined as products containing specified natural ingredients, such as vitamins, minerals, amino acids, or plant, algal, bacterial, fungal, or non-human animal materials or extracts, which are intended for use in: (a) diagnosis, treatment, mitigation or prevention of a disease, disorder or abnormal physical state; (b) restoring or correcting organic function; or (c) modifying organic functions.4

The database of licensed NHPs demonstrates the variety of different products approved as NHPs in Canada. In addition to products such as vitamin tablets that would be classified as dietary supplements in the U.S., additional products are regulated as NHPs in Canada, including certain anti-dandruff shampoos, toothpastes, mouthwashes, antiperspirants, and antiseptic ointments and lotions, depending on both the ingredients of the products and the marketing claims made about those products.

Since NHPs are regulated as drugs, the marketing and sale of these products in Canada requires site license approval for a manufacturer and/or importer, as well as license approval of the product itself. Submission of evidence satisfying product safety, efficacy, and quality is generally required. Further, after licensing, NHP manufacturers and importers are subject to continuing regulatory obligations relating, for example, to labelling and marketing, record keeping and reporting of adverse events.

As a result of this more rigorous regulation, however, dietary supplements sold in Canada may be allowed to make more drug-like marketing claims, such as claims to the treatment or prevention of particular diseases or conditions (provided these claims are within the scope of the product's Canadian NHP license).

NHP Licensing

In practice, product safety and efficacy are handled differently by the U.S. and Canadian regulatory systems for dietary supplements. In the U.S., there is no pre-approval requirement, and the FDA must demonstrate that a product is unsafe before it may take action to remove the product from the market. Conversely, in Canada, the manufacturer or importer must demonstrate to Health Canada that the product is safe, effective, and of sufficient quality before a license will be issued and the product can be marketed for sale.

As mentioned above, a site license is required to manufacture, package, label or import an NHP for sale in Canada5. A site license may be required, for example, even if an importer immediately ships the product to retailers after entry into Canada without first storing the product.6 To obtain a valid site license for a particular NHP, an entity must submit Quality Assurance Reports for both the import site and for any foreign manufacturing sites to demonstrate compliance with Good Manufacturing Practices (GMP). Site licenses will only be granted for domestic Canadian sites; therefore, the NHP license holder is responsible for ensuring GMP compliance of a foreign manufacturer.

In addition to site licensing, Health Canada also requires NHPs to be licensed before marketing and sale in Canada.7 In order to streamline the licensing process, Health Canada has published monographs for ingredients that are commonly found in NHPs. These monographs list previously approved doses, administration methods, indications and claims that can be made with respect to a particular ingredient. Applications for NHPs that conform to the specifications of existing monographs can generally receive approval without further safety and efficacy data. Currently, Health Canada has established three target timelines for responding to NHP licensing applications, depending on the complexity and novelty of the application. Applications indexed against a single ingredient monograph will be reviewed and licensed within 10 days. Applications indexed against multiple monographs are targeted for review within 30 days.

Finally, applications with higher uncertainty, such as those with previously unlicensed claims for serious conditions, never-before reviewed ingredients or combinations, or products with safety concerns are targeted for review within 180 days.8

Health Canada takes a risk-based approach to evaluating safety and efficacy.9 The level of risk associated with an application will depend on the medicinal and non-medicinal ingredients, as well as the recommended use and proposed health claims. Products that bear claims to treat, cure, or prevent serious diseases will attract a higher risk classification, while products directed at general health maintenance or which are directed at minor symptoms or diseases will attract a low-risk classification.

The minimum standard of safety and efficacy evidence depends on the risk categorization of an application. For low-risk products, references to human in vivo data in reputable textbooks regarding medicinal and non-medicinal ingredients may suffice. For high-risk products, Health Canada may require clinical trials.10 Health Canada will also consider positive decisions regarding health and efficacy from other regulatory agencies; however, this may be of limited assistance to exporters of U.S. dietary supplements as licensing approval for these products is not required to enter the U.S. market.11


Health Canada requires NHPs to carry specific information on inner and outer labels, reflecting their status as drugs.12 The labels must include medicinal and non-medicinal ingredients, lot numbers, expiry dates, and recommendations for use, including dosage, frequency, and route of administration. A description of the source of each medicinal ingredient must also be provided. Information on labels must be consistent with the information provided in the NHP licensing application, and labels cannot include claims beyond the scope of the license granted by Health Canada.

Certain text on labels must be provided in both English and French, including recommendations for administration, dosage and duration of use, risk information and known adverse reactions, medicinal and non-medicinal ingredients, and appropriate storage conditions.13 his text must be bilingual regardless of whether or not the product is sold in Quebec. If the product is sold in Quebec, additional French language requirements apply, including fully bilingual text and equal prominence of French and English text.14

Post-Licensing Product Changes

Health Canada must be notified if changes are made to the product after licensing. For minor changes with no significant impact on safety, efficacy or quality, Health Canada must be notified within 60 days of the change. Where changes may impact safety, efficacy or quality, Health Canada must approve the change through an amendment to the product license before it is implemented. In cases of fundamental changes to the product, Health Canada may require that a new license be issued, based on fresh supporting evidence of safety, efficacy and quality. Also, if Health Canada changes an ingredient monograph that is related to an NHP, the manufacturer or importer must submit either a notice of change or proposed amendment, depending on the impact of the change to the monograph.15

Adverse Event Reporting

As with prescription drugs, NHP licensees must report adverse events to Health Canada. Under the NHP Regulations, individual case reports must be sent to Health Canada within 15 days for each serious adverse reaction that occurs in Canada, and for each serious and unexpected adverse reaction domestically or internationally. Further, Health Canada requires annual reports to be prepared compiling all adverse reactions inside Canada and individual case reports as required above.16

Advertising of NHPs in Canada

Advertising for drugs in Canada, including NHPs, may be reviewed by Advertising Standards Canada (ASC), a self-regulatory body of the Canadian advertising industry. Although there is no legal requirement to submit proposed advertisements to ASC for review, as a practical matter, the majority of print and broadcast media outlets will not run advertisements without ASC approval. Although ASC is independent from Health Canada, it will review advertisements for compliance with Health Canada regulations.17 ASC will generally provide a review within four business days for a nominal fee, and will grant an ASC approval number that can then be provided to media outlets.

For television advertising, manufacturers and importers should also seek approval from the Television Bureau of Canada (TVB), a non-profit association that operates on behalf of the major Canadian television broadcasters, meaning that without TVB approval, the avenues for television advertising may be limited. Costs for review and approval of advertising by TVB are paid by member television broadcasters, with reviews generally provided within one to three business days, and same-day review available for a nominal fee. Each version of a television advertisement should receive its own review and approval from TVB.

Unintentional Export

If a dietary supplement is not marketed or sold in Canada, and there is no intent to export the product to the Canadian market, U.S. manufacturers and distributors should still understand the implications of cross-border "spillover" of the product. Generally speaking, Health Canada has taken the position that where there is no intent to export and no marketing or sales operations are active in Canada, domestic Canadian drug regulations would not apply.18 Further, individuals are permitted to cross the border with a three-month personal supply of a dietary supplement that has not been approved for sale in Canada, since this amount is regarded as insufficient for commercial sales.19 However, Health Canada has issued blanket prohibitions on the import of particular products and ingredients into Canada. Health Canada regularly issues recalls and press releases regarding particular NHPs that contain prohibited or toxic ingredients. A current list of product recalls, alerts, and advisories may be found on the Health Canada website.20


Because of the differences in classification of dietary supplements as foods in the U.S. and NHPs (a class of drug) in Canada, any manufacturer who seeks to export a dietary supplement to Canada will want to be aware of applicable Canadian regulations.

Originally published by FDLI's Update.


1. 108 Stat. 4325.

2. In some circumstances, if the dietary supplement is in a particularly food-like form, is packaged and represented as a food product, and is perceived by the public as a food product, Health Canada is may classify a dietary supplement a food. Health Canada's policy, for example, is to classify energy drinks as foods: (

3. Natural Health Products Directorate, Food Directorate, Classification of Products at the Food-Natural Health Product Interface: Products in Food Formats (June, 2010); Health Canada, Foods Marketed as Natural Health Products, online (

4. Natural Health Products Regulations, S.O.R./2003-196, s. 1 [NHP Regulations].

5. NHP Regulations, supra note 4 s. 27.

6. NHP Regulations, ibid; see Natural Health Products Directorate, Site Licensing Guidance Document, (September 2007), online (

7. NHP Regulations, supra note 4 s. 4; see Natural Health Products Directorate, Pathway for Licensing Natural Health Products Making Modern Health Claims, (December 2012), online ( [Licensing Pathway]; see also Natural Health Products Directorate, Pathway for Licensing Natural Health Products used as Traditional Medicines, (December 2012), online (

8. Health Canada, The approach to natural health products, online (

9. Licensing Pathway, supra note 7.

10. Ibid.

11. Ibid.

12. NHP Regulations, supra note 4 s. 86; see Natural Health Products Directorate, Labelling Guidance Document, (August 2006), online ( [Labelling Guidance]; see also Health Canada, Labelling Requirements Checklist, (April 2011), online (

13. NHP Regulations, supra note 4 s. 87; Labelling Guidance, supra note 12.

14. Charter of the French Language, C.Q.L.R. c. C-11, s. 51.

15. NHP Regulations, supra note 4 ss. 11-13; see Natural Health Products Directorate, Post Licensing Guidance Document, (December 2007), online (

16. NHP Regulations, supra note 4 s. 24; see Health Canada, Guidance Document for Industry – Reporting Adverse Reactions to Marketed Health Products, (2 March 2011), online (

17. see e.g. Health Canada, Guidance Document: Consumer Advertising Guidelines for Marketed Health Products (for Nonprescription Drugs including Natural Health Products), (18 October 2006), online (

18. see Health Products and Food Branch Inspectorate, Import and Export Policy for Health Products Under the Food and Drugs Act and its Regulations, POL-0060, (1 June 2010), online (

19. Ibid.

20. Online (

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.